Go Pro
→ Why major institutions are piling into this digital asset now (From Awesomely) (Ad)tc pixel Free TWST Stock Alerts

Twist Bioscience (TWST) Financials

Twist Bioscience logo
$141.38 -11.72 (-7.66%)
As of 08/28/2026 04:00 PM Eastern
Compare
Annual Income Statements for Twist Bioscience

Annual Income Statements for Twist Bioscience

This table shows Twist Bioscience's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 9/30/2017 9/30/2018 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024 9/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 -59 -71 -108 -140 -152 -218 -205 -209 -78
Consolidated Net Income / (Loss)		 -59 -71 -108 -140 -152 -218 -205 -209 -78
Net Income / (Loss) Continuing Operations		 -59 -71 -108 -140 -152 -218 -205 -209 -78
Total Pre-Tax Income 		-59 -71 -107 -140 -154 -228 -203 -208 -77
Total Operating Income		 -58 -71 -109 -140 -153 -235 -217 -221 -136
Total Gross Profit		 -13 -6.76 6.96 29 52 84 90 133 191
Total Revenue		 11 25 54 90 132 204 245 313 377
Operating Revenue		 11 25 54 90 132 204 245 313 377
Total Cost of Revenue		 24 32 47 61 81 119 155 180 186
Operating Cost of Revenue		 24 32 47 61 81 119 155 180 186
Total Operating Expenses		 45 64 116 169 204 319 307 354 327
Selling, General & Admin Expense		 26 43 80 103 136 213 190 218 247
Research & Development Expense		 19 20 36 43 69 120 107 91 80
Other Operating Expenses / (Income)		 - - 0.00 0.00 -0.53 -14 -5.91 0.00 0.00
Impairment Charge		 - - - - - 0.00 6.79 45 0.00
Restructuring Charge		 - - - - 0.00 0.00 9.38 0.00 0.00
Total Other Income / (Expense), net		 -0.55 -0.44 1.47 0.53 -1.30 6.50 14 13 59
Interest & Investment Income		 0.41 1.00 3.03 1.50 0.44 7.67 14 15 11
Other Income / (Expense), net		 -0.06 -0.12 -0.27 -0.18 -1.37 -1.09 -0.67 -2.68 48
Income Tax Expense		 0.28 0.24 0.29 0.38 -1.93 -10 1.15 0.56 0.72
Basic Earnings per Share		 ($24.49) ($25.51) ($3.92) ($3.57) ($3.15) ($4.04) ($3.60) ($3.60) ($1.30)
Weighted Average Basic Shares Outstanding		 2.42M 2.79M 27.46M 39.19M 48.25M 53.89M 56.89M 58.02M 59.81M
Diluted Earnings per Share		 ($24.49) ($25.51) ($3.92) ($3.57) ($3.15) ($4.04) ($3.60) ($3.60) ($1.30)
Weighted Average Diluted Shares Outstanding		 2.42M 2.79M 27.46M 39.19M 48.25M 53.89M 56.89M 58.02M 59.81M
Weighted Average Basic & Diluted Shares Outstanding		 2.42M 2.79M 27.46M 39.19M 48.25M 56.57M 57.67M 59.36M 61.15M

Quarterly Income Statements for Twist Bioscience

This table shows Twist Bioscience's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -43 -45 -86 -35 -32 -39 20 -27 -31 -44 -35
Consolidated Net Income / (Loss)		 -43 -45 -86 -35 -32 -39 20 -27 -31 -44 -35
Net Income / (Loss) Continuing Operations		 -43 -45 -86 -35 -32 -39 20 -27 -31 -44 -35
Total Pre-Tax Income 		-43 -45 -85 -35 -31 -39 21 -27 -30 -44 -35
Total Operating Income		 -47 -49 -89 -36 -35 -42 -30 -30 -33 -46 -36
Total Gross Profit		 29 31 35 38 43 46 51 51 54 57 62
Total Revenue		 71 75 81 85 89 93 96 99 104 111 118
Operating Revenue		 71 75 81 85 89 93 96 99 104 111 118
Total Cost of Revenue		 43 44 46 46 46 47 45 48 50 54 56
Operating Cost of Revenue		 43 44 46 46 46 47 45 48 50 54 56
Total Operating Expenses		 76 80 124 74 77 88 81 81 87 103 99
Selling, General & Admin Expense		 53 56 57 53 56 64 63 64 70 76 81
Research & Development Expense		 23 24 22 21 21 24 18 17 17 20 18
Other Special Charges / (Income)		 - - - - - 0.00 0.00 - - 7.21 0.00
Total Other Income / (Expense), net		 4.09 3.74 3.54 1.29 3.15 2.41 51 3.05 2.65 1.89 1.54
Interest & Investment Income		 4.12 3.94 3.66 3.62 3.24 2.80 2.69 2.63 2.18 1.71 1.50
Other Income / (Expense), net		 -0.03 -0.20 -0.12 -2.30 -0.09 -0.39 48 0.25 0.47 0.18 0.04
Income Tax Expense		 0.12 0.35 0.19 -0.10 0.10 0.18 0.19 0.26 0.25 0.04 0.31
Basic Earnings per Share		 ($0.75) ($0.79) ($1.47) ($0.59) ($0.53) ($0.66) $0.34 ($0.45) ($0.50) ($0.71) ($0.56)
Weighted Average Basic Shares Outstanding		 57.50M 57.78M 58.15M 58.02M 59.16M 59.65M 60.00M 59.81M 61.08M 61.70M 62.40M
Diluted Earnings per Share		 ($0.75) ($0.79) ($1.47) ($0.59) ($0.53) ($0.66) $0.33 ($0.44) ($0.50) ($0.71) ($0.56)
Weighted Average Diluted Shares Outstanding		 57.50M 57.78M 58.15M 58.02M 59.16M 59.65M 61.16M 59.81M 61.08M 61.70M 62.40M
Weighted Average Basic & Diluted Shares Outstanding		 57.82M 58.23M 58.59M 59.36M 59.65M 59.92M 60.36M 61.15M 61.31M 62.27M 62.71M

Annual Cash Flow Statements for Twist Bioscience

This table details how cash moves in and out of Twist Bioscience's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 9/30/2017 9/30/2018 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024 9/30/2025
Net Change in Cash & Equivalents		 2.51 50 -34 47 373 -87 -91 -60 -44
Net Cash From Operating Activities		 -51 -66 -88 -142 -112 -124 -142 -64 -48
Net Cash From Continuing Operating Activities		 -51 -66 -88 -142 -113 -124 -142 -64 -48
Net Income / (Loss) Continuing Operations		 -59 -71 -108 -140 -152 -218 -205 -209 -78
Consolidated Net Income / (Loss)		 -59 -71 -108 -140 -152 -218 -205 -209 -78
Depreciation Expense		 5.02 5.73 6.11 6.68 9.75 17 29 31 25
Non-Cash Adjustments To Reconcile Net Income		 3.02 3.26 12 16 39 97 40 98 18
Changes in Operating Assets and Liabilities, net		 -0.13 -4.22 3.00 -25 -9.38 -20 -6.92 15 -13
Net Cash From Investing Activities		 -9.99 27 -105 -115 156 -233 51 -3.07 -25
Net Cash From Continuing Investing Activities		 -9.99 27 -105 -115 156 -233 51 -3.07 -25
Purchase of Property, Plant & Equipment		 -6.59 -3.69 -15 -9.87 -27 -102 -28 -5.08 -28
Purchase of Investments		 -41 -3.52 -178 -203 -59 -218 -76 -52 -49
Divestitures		 - - - - - - 0.00 0.00 2.50
Sale and/or Maturity of Investments		 37 35 88 98 242 100 155 54 50
Net Cash From Financing Activities		 64 89 159 304 329 271 0.91 6.89 29
Net Cash From Continuing Financing Activities		 64 89 159 304 329 271 0.91 6.89 29
Repurchase of Common Equity		 0.00 -2.36 0.00 -2.42 -11 -7.75 -4.41 -3.98 -0.02
Issuance of Debt		 2.17 - - - - - 0.00 0.00 15
Issuance of Common Equity		 0.21 0.33 158 306 338 280 1.38 7.10 9.34
Other Financing Activities, net		 - - 2.70 3.43 4.94 - 3.94 3.77 4.21
Effect of Exchange Rate Changes		 - - 0.03 0.02 0.02 -0.32 -0.03 0.13 0.14
Cash Income Taxes Paid		 0.01 0.18 0.29 0.17 0.10 0.25 0.42 0.34 0.68

Quarterly Cash Flow Statements for Twist Bioscience

This table details how cash moves in and out of Twist Bioscience's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -20 -23 -4.18 -13 -5.07 -11 -9.04 -18 -34 -26 -5.29
Net Cash From Operating Activities		 -23 -19 -6.38 -15 -21 -13 -1.40 -12 -25 -18 1.12
Net Cash From Continuing Operating Activities		 -23 -19 -6.38 -15 -21 -13 -1.40 -12 -25 -18 1.12
Net Income / (Loss) Continuing Operations		 -43 -45 -86 -35 -32 -39 20 -27 -31 -44 -35
Consolidated Net Income / (Loss)		 -43 -45 -86 -35 -32 -39 20 -27 -31 -44 -35
Depreciation Expense		 8.17 8.30 8.30 6.66 6.38 6.40 6.07 6.00 6.19 6.41 6.78
Non-Cash Adjustments To Reconcile Net Income		 11 14 58 14 12 21 -32 16 13 18 18
Changes in Operating Assets and Liabilities, net		 0.53 3.46 13 -1.14 -8.19 -1.22 3.78 -6.98 -13 1.61 11
Net Cash From Investing Activities		 4.17 -5.24 -0.71 -1.29 -1.54 -1.43 -9.40 -12 -9.93 -13 -10
Net Cash From Continuing Investing Activities		 4.17 -5.24 -0.71 -1.29 -1.54 -1.43 -9.40 -12 -9.93 -13 -10
Purchase of Property, Plant & Equipment		 -1.51 -0.60 -0.97 -2.00 -2.27 -4.14 -9.17 -12 -9.97 -13 -9.76
Purchase of Investments		 -18 -11 -1.75 -21 -21 -4.93 -2.73 -21 -21 -4.72 -13
Sale and/or Maturity of Investments		 24 6.00 2.00 22 21 7.65 - 21 21 5.00 13
Net Cash From Financing Activities		 -1.47 1.83 2.91 3.63 18 3.20 1.83 5.57 0.30 4.14 3.79
Net Cash From Continuing Financing Activities		 -1.47 1.83 2.91 3.63 18 3.20 1.83 5.57 0.30 4.14 3.79
Repurchase of Common Equity		 -2.42 -1.54 -0.01 -0.01 -0.01 -0.01 -0.00 -0.00 -0.00 -0.01 -0.01
Issuance of Common Equity		 0.95 1.32 2.92 5.68 2.95 0.77 1.83 3.79 0.30 1.79 3.79
Effect of Exchange Rate Changes		 0.12 -0.07 0.00 0.07 -0.05 0.10 -0.07 0.16 0.01 -0.01 0.01
Cash Income Taxes Paid		 0.04 0.30 0.02 -0.02 0.00 0.01 0.01 0.66 0.18 0.47 -0.13

Annual Balance Sheets for Twist Bioscience

This table presents Twist Bioscience's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 9/30/2018 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024 9/30/2025
Total Assets		 116 187 399 702 961 776 614 642
Total Current Assets		 96 160 335 546 596 424 347 333
Cash & Equivalents		 81 47 94 466 379 286 226 183
Short-Term Investments		 0.00 91 196 12 126 50 50 49
Accounts Receivable		 5.42 12 26 29 40 44 35 57
Inventories, net		 6.03 7.33 12 32 39 32 24 28
Prepaid Expenses		 3.47 2.59 6.20 8.28 12 12 11 15
Plant, Property, & Equipment, net		 12 21 25 44 139 132 103 102
Total Noncurrent Assets		 7.79 6.02 39 111 225 220 165 207
Long-Term Investments		 - - - - - - 1.53 54
Goodwill		 1.14 1.14 1.14 22 86 86 86 82
Intangible Assets		 0.71 0.51 0.31 18 60 54 14 13
Other Noncurrent Operating Assets		 5.94 4.38 37 71 80 80 63 57
Total Liabilities & Shareholders' Equity		 116 187 399 702 961 776 614 642
Total Liabilities		 27 35 63 121 172 153 142 169
Total Current Liabilities		 19 30 36 63 91 73 71 91
Accounts Payable		 7.53 9.76 4.83 15 20 14 1.63 11
Current Employee Benefit Liabilities		 5.40 10 15 22 27 26 34 31
Other Current Liabilities		 0.94 0.82 9.02 18 33 23 21 49
Total Noncurrent Liabilities		 8.19 4.56 27 58 81 80 71 77
Noncurrent Deferred Revenue		 - - - - - - 0.00 15
Other Noncurrent Operating Liabilities		 0.98 0.16 25 58 81 80 71 62
Commitments & Contingencies		 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -201 152 336 581 789 623 473 473
Total Preferred & Common Equity		 -201 152 336 581 789 623 473 473
Total Common Equity		 -201 152 336 581 789 623 473 473
Common Stock		 9.35 470 795 1,191 1,620 1,657 1,715 1,793
Retained Earnings		 -211 -319 -458 -611 -828 -1,033 -1,242 -1,320
Accumulated Other Comprehensive Income / (Loss)		 0.09 0.18 0.09 0.55 -1.84 -0.76 -0.52 -0.63

Quarterly Balance Sheets for Twist Bioscience

This table presents Twist Bioscience's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2023 6/30/2023 12/31/2023 3/31/2024 6/30/2024 12/31/2024 3/31/2025 6/30/2025 12/31/2025 3/31/2026 6/30/2026
Total Assets		 854 810 733 703 638 609 596 644 638 676 672
Total Current Assets		 489 446 390 372 362 345 338 340 304 323 321
Cash & Equivalents		 315 307 266 243 239 221 210 201 149 123 117
Short-Term Investments		 72 50 45 50 50 49 47 49 49 49 49
Accounts Receivable		 48 43 35 36 32 39 50 50 50 64 65
Inventories, net		 40 36 31 30 28 24 21 26 33 34 35
Prepaid Expenses		 14 9.46 13 12 12 12 10 13 23 54 54
Plant, Property, & Equipment, net		 147 141 126 121 106 101 97 95 105 111 112
Total Noncurrent Assets		 218 224 216 210 170 163 160 208 229 242 239
Long-Term Investments		 - - - - - - - 54 54 68 68
Goodwill		 86 86 86 86 86 86 86 82 82 82 82
Intangible Assets		 57 56 53 52 15 14 14 14 13 13 13
Other Noncurrent Operating Assets		 75 82 77 72 69 63 60 58 79 78 76
Total Liabilities & Shareholders' Equity		 854 810 733 703 638 609 596 644 638 676 672
Total Liabilities		 150 153 143 143 147 153 156 165 182 221 227
Total Current Liabilities		 72 73 65 67 74 70 75 87 80 120 120
Accounts Payable		 13 12 9.26 7.70 6.63 7.50 8.06 12 12 15 17
Current Employee Benefit Liabilities		 24 27 21 25 32 22 25 29 19 27 35
Other Current Liabilities		 23 23 21 20 21 20 22 27 26 78 68
Total Noncurrent Liabilities		 78 80 78 75 73 83 81 78 102 101 106
Noncurrent Deferred Revenue		 - - - - - 15 15 15 15 15 15
Other Noncurrent Operating Liabilities		 78 80 78 75 73 68 66 63 87 86 91
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 704 658 590 560 491 456 440 478 456 455 446
Total Preferred & Common Equity		 704 658 590 560 491 456 440 478 456 455 446
Total Common Equity		 704 658 590 560 491 456 440 478 456 455 446
Common Stock		 1,633 1,645 1,667 1,682 1,699 1,730 1,754 1,772 1,807 1,850 1,876
Retained Earnings		 -929 -987 -1,076 -1,122 -1,207 -1,274 -1,313 -1,292 -1,350 -1,394 -1,429
Accumulated Other Comprehensive Income / (Loss)		 0.11 -0.64 -0.57 -0.66 -0.74 -0.65 -0.66 -0.86 -0.57 -0.64 -0.66

Annual Metrics And Ratios for Twist Bioscience

This table displays calculated financial ratios and metrics derived from Twist Bioscience's official financial filings.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 9/30/2017 9/30/2018 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024 9/30/2025
Growth Metrics		 - - - - - - - - -
Revenue Growth		 0.00% 136.16% 113.89% 65.67% 46.87% 53.83% 20.41% 27.69% 20.32%
EBITDA Growth		 0.00% -21.01% -60.83% -28.51% -8.43% -51.40% 11.36% 1.22% 66.96%
EBIT Growth		 0.00% -20.74% -54.38% -28.54% -9.86% -53.06% 7.65% -2.60% 60.49%
NOPAT Growth		 0.00% -20.65% -54.27% -28.69% -9.03% -53.72% 7.50% -1.69% 38.30%
Net Income Growth		 0.00% -20.11% -51.14% -29.96% -8.70% -43.24% 6.08% -2.01% 62.79%
EPS Growth		 0.00% -4.17% 84.63% 8.93% 11.76% -28.25% 10.89% 0.00% 63.89%
Operating Cash Flow Growth		 0.00% -28.97% -32.91% -61.77% 21.10% -10.82% -14.54% 55.01% 25.69%
Free Cash Flow Firm Growth		 0.00% 0.00% -18.49% -59.42% -25.98% -114.59% 55.09% 58.70% -39.27%
Invested Capital Growth		 0.00% 0.00% 20.45% 134.92% 104.94% 172.14% 0.91% -31.61% -4.40%
Revenue Q/Q Growth		 0.00% 0.00% 15.58% 22.75% 4.35% 10.51% 4.09% 6.02% 3.95%
EBITDA Q/Q Growth		 0.00% 0.00% -13.00% 5.80% -13.66% 0.08% 2.32% 5.03% 11.20%
EBIT Q/Q Growth		 0.00% 0.00% -12.15% 5.11% -12.28% -7.50% 3.10% 5.10% 8.93%
NOPAT Q/Q Growth		 0.00% 0.00% -12.23% 5.15% -11.57% -7.84% 3.02% 5.99% 4.29%
Net Income Q/Q Growth		 0.00% 0.00% -11.82% 4.68% -12.52% -4.75% 2.33% 5.26% 8.82%
EPS Q/Q Growth		 0.00% 0.00% 59.25% 12.93% -17.54% -2.28% 2.97% 5.76% 10.34%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -8.20% -1.31% -9.35% 21.24% -15.80% 7.75% 6.86%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -3.20% -9.48% 2.22% 5.76% 2.88% -22.26%
Invested Capital Q/Q Growth		 0.00% 0.00% -4.24% 19.46% 11.89% -2.96% -4.46% -2.69% 7.58%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 -123.09% -26.59% 12.80% 31.85% 39.08% 41.38% 36.61% 42.61% 50.72%
EBITDA Margin		 -496.15% -254.24% -191.18% -148.30% -109.48% -107.75% -79.32% -61.36% -16.85%
Operating Margin		 -543.16% -277.50% -200.15% -155.47% -115.41% -115.33% -88.60% -70.56% -36.18%
EBIT Margin		 -543.67% -277.97% -200.63% -155.67% -116.45% -115.87% -88.87% -71.41% -23.45%
Profit (Net Income) Margin		 -550.85% -280.16% -197.98% -155.31% -114.94% -107.02% -83.48% -66.69% -20.63%
Tax Burden Percent		 100.47% 100.34% 100.27% 100.27% 98.75% 95.44% 100.57% 100.27% 100.93%
Interest Burden Percent		 100.84% 100.44% 98.41% 99.49% 99.96% 96.78% 93.41% 93.15% 87.13%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -548.12% -383.56% -269.74% -137.50% -84.51% -53.20% -63.97% -50.08%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -486.62% -352.31% -249.59% -125.63% -73.60% -40.70% -46.30% -56.35%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 388.15% 294.27% 212.43% 104.33% 52.71% 24.24% 25.88% 33.65%
Return on Equity (ROE)		 0.00% -159.97% -89.30% -57.31% -33.17% -31.80% -28.97% -38.08% -16.43%
Cash Return on Invested Capital (CROIC)		 0.00% -748.12% -402.12% -350.31% -206.32% -177.03% -54.11% -26.42% -45.57%
Operating Return on Assets (OROA)		 0.00% -61.04% -72.07% -47.88% -27.99% -28.36% -25.07% -32.14% -14.06%
Return on Assets (ROA)		 0.00% -61.52% -71.12% -47.77% -27.63% -26.19% -23.55% -30.02% -12.37%
Return on Common Equity (ROCE)		 0.00% 361.79% 18.27% -57.31% -33.17% -31.80% -28.97% -38.08% -16.43%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 35.37% -70.80% -41.61% -26.19% -27.60% -32.82% -44.16% 0.00%
Net Operating Profit after Tax (NOPAT)		 -41 -49 -76 -98 -107 -164 -152 -155 -95
NOPAT Margin		 -380.21% -194.25% -140.10% -108.83% -80.79% -80.73% -62.02% -49.39% -25.33%
Net Nonoperating Expense Percent (NNEP)		 0.00% -61.50% -31.25% -20.15% -11.87% -10.91% -12.50% -17.67% 6.27%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -20.17%
Cost of Revenue to Revenue		 223.09% 126.59% 87.20% 68.15% 60.92% 58.62% 63.39% 57.39% 49.28%
SG&A Expenses to Revenue		 242.04% 170.88% 147.33% 114.61% 102.70% 104.61% 77.41% 69.78% 65.59%
R&D to Revenue		 178.03% 80.02% 65.61% 47.73% 52.20% 59.10% 43.61% 29.03% 21.32%
Operating Expenses to Revenue		 420.07% 250.90% 212.94% 187.32% 154.49% 156.71% 125.20% 113.17% 86.91%
Earnings before Interest and Taxes (EBIT)		 -59 -71 -109 -140 -154 -236 -218 -223 -88
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -53 -65 -104 -134 -145 -219 -194 -192 -63
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 5.11 10.09 9.08 2.52 1.87 5.60 3.59
Price to Tangible Book Value (P/TBV)		 0.00 0.00 5.17 10.13 9.76 3.09 2.41 7.11 4.50
Price to Revenue (P/Rev)		 6.50 2.75 14.30 37.66 39.84 9.76 4.74 8.46 4.51
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 16.06 29.81 60.94 45.89 5.21 2.88 12.08 7.58
Enterprise Value to Revenue (EV/Rev)		 0.00 11.38 11.90 34.49 36.25 7.28 3.37 7.57 3.75
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.00 0.11 0.05 0.01 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.08 0.03 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -0.80 -0.84 -0.85 -0.83 -0.72 -0.60 -0.56 -0.60
Leverage Ratio		 0.00 1.30 1.26 1.20 1.20 1.21 1.23 1.27 1.33
Compound Leverage Factor		 0.00 1.31 1.24 1.19 1.20 1.18 1.15 1.18 1.16
Debt to Total Capital		 0.00% 9.84% 4.84% 1.39% 0.27% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 2.53% 2.09% 0.98% 0.27% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 7.31% 2.75% 0.41% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 294.07% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -203.91% 95.16% 98.61% 99.73% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 -0.15 -0.07 -0.04 -0.01 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 1.10 1.25 2.14 3.29 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 -0.11 -0.04 -0.01 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.20 -0.10 -0.05 -0.01 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 1.44 1.71 2.91 4.46 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 -0.15 -0.06 -0.01 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 -1.97 10.18 30.87 25.16 5.76 2.63 8.23 3.74
Noncontrolling Interest Sharing Ratio		 0.00% 326.16% 120.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 0.00 5.16 5.28 9.29 8.67 6.58 5.79 4.88 3.64
Quick Ratio		 0.00 4.65 4.95 8.78 8.03 6.01 5.19 4.38 3.17
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -67 -80 -127 -160 -344 -155 -64 -87
Operating Cash Flow to CapEx		 -810.70% -1,802.34% -596.75% -1,441.58% -414.78% -122.12% -512.88% -1,262.69% -170.08%
Free Cash Flow to Firm to Interest Expense		 0.00 -51.34 -61.73 -161.81 -437.12 -4,303.13 -30,922.66 -2,201.82 0.00
Operating Cash Flow to Interest Expense		 -56.69 -50.39 -67.96 -180.76 -305.84 -1,554.81 -28,494.80 -2,210.14 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -63.68 -53.19 -79.35 -193.29 -379.58 -2,828.03 -34,050.60 -2,385.17 0.00
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.00 0.22 0.36 0.31 0.24 0.24 0.28 0.45 0.60
Accounts Receivable Turnover		 0.00 4.69 6.21 4.68 4.82 5.91 5.81 7.93 8.19
Inventory Turnover		 0.00 5.34 7.10 6.26 3.66 3.36 4.35 6.40 7.08
Fixed Asset Turnover		 0.00 2.06 3.28 3.89 3.80 2.22 1.81 2.67 3.68
Accounts Payable Turnover		 0.00 4.27 5.49 8.42 8.17 6.82 9.10 22.91 29.17
Days Sales Outstanding (DSO)		 0.00 77.79 58.80 77.94 75.75 61.72 62.81 46.05 44.55
Days Inventory Outstanding (DIO)		 0.00 68.35 51.40 58.31 99.80 108.75 83.83 57.04 51.52
Days Payable Outstanding (DPO)		 0.00 85.40 66.54 43.36 44.66 53.52 40.10 15.93 12.51
Cash Conversion Cycle (CCC)		 0.00 60.75 43.67 92.89 130.89 116.95 106.53 87.15 83.56
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 0.00 18 22 51 105 284 287 196 186
Invested Capital Turnover		 0.00 2.82 2.74 2.48 1.70 1.05 0.86 1.30 1.98
Increase / (Decrease) in Invested Capital		 0.00 18 3.69 29 54 180 2.60 -91 -8.58
Enterprise Value (EV)		 0.00 289 647 3,108 4,796 1,481 826 2,371 1,412
Market Capitalization		 70 70 778 3,393 5,273 1,986 1,163 2,647 1,699
Book Value per Share		 $0.00 ($72.12) $4.67 $7.53 $11.78 $14.01 $10.86 $8.07 $7.84
Tangible Book Value per Share		 $0.00 ($72.78) $4.62 $7.50 $10.96 $11.42 $8.42 $6.36 $6.25
Total Capital		 0.00 99 160 341 582 789 623 473 473
Total Debt		 0.00 9.72 7.73 4.74 1.55 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 7.22 4.40 1.40 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -71 -130 -285 -476 -505 -336 -276 -287
Capital Expenditures (CapEx)		 6.33 3.67 15 9.87 27 102 28 5.08 28
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -1.12 -4.99 12 7.13 0.85 15 -0.63 9.13
Debt-free Net Working Capital (DFNWC)		 0.00 80 133 302 485 506 351 276 242
Net Working Capital (NWC)		 0.00 77 130 299 483 506 351 276 242
Net Nonoperating Expense (NNE)		 18 22 31 42 45 54 53 54 -18
Net Nonoperating Obligations (NNO)		 0.00 -71 -130 -285 -476 -505 -336 -276 -287
Total Depreciation and Amortization (D&A)		 5.12 6.04 5.14 6.65 9.22 17 23 31 25
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -4.42% -9.18% 13.51% 5.39% 0.42% 5.92% -0.20% 2.42%
Debt-free Net Working Capital to Revenue		 0.00% 313.19% 244.76% 335.38% 366.50% 248.48% 143.17% 88.11% 64.15%
Net Working Capital to Revenue		 0.00% 303.35% 238.63% 331.68% 365.32% 248.48% 143.17% 88.11% 64.15%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($3.92) ($3.57) ($3.15) $0.00 ($3.60) ($3.60) ($1.30)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 33.12M 45.15M 49.63M 0.00 56.89M 58.02M 59.81M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($3.92) ($3.57) ($3.15) $0.00 ($3.60) ($3.60) ($1.30)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 33.12M 45.15M 49.63M 0.00 56.89M 58.02M 59.81M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($3.92) ($3.57) ($3.15) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 27.46M 39.19M 48.25M 0.00 57.67M 59.36M 61.15M
Normalized Net Operating Profit after Tax (NOPAT)		 -41 -49 -76 -82 -107 -164 -141 -123 -95
Normalized NOPAT Margin		 -380.21% -194.25% -140.10% -91.35% -80.79% -80.73% -57.40% -39.34% -25.33%
Pre Tax Income Margin		 -548.25% -279.21% -197.44% -154.88% -116.39% -112.14% -83.01% -66.51% -20.43%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 -64.68 -53.83 -84.32 -178.22 -419.88 -2,948.29 -43,565.20 -7,706.24 0.00
NOPAT to Interest Expense		 -45.23 -37.62 -58.88 -124.59 -291.30 -2,054.29 -30,402.26 -5,330.40 0.00
EBIT Less CapEx to Interest Expense		 -71.67 -56.63 -95.71 -190.76 -493.62 -4,221.50 -49,121.00 -7,881.28 0.00
NOPAT Less CapEx to Interest Expense		 -52.23 -40.41 -70.27 -137.13 -365.04 -3,327.50 -35,958.06 -5,505.44 0.00
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -3.31% 0.00% -1.73% -7.13% -3.56% -2.15% -1.90% -0.02%

Quarterly Metrics And Ratios for Twist Bioscience

This table displays calculated financial ratios and metrics derived from Twist Bioscience's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - 61,148,026.00 122,623,408.00 62,271,314.00
DEI Adjusted Shares Outstanding		 - - - - - - - - 61,148,026.00 122,623,408.00 62,271,314.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - -0.50 -0.36 -0.56
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 31.81% 25.13% 27.81% 26.53% 24.08% 23.23% 17.91% 16.88% 16.89% 19.31% 23.24%
EBITDA Growth		 1.67% 25.73% -54.53% 24.30% 27.05% 13.18% 129.67% 25.34% 7.48% -10.48% -222.98%
EBIT Growth		 -4.96% 20.75% -46.60% 23.86% 26.16% 14.82% 120.09% 22.64% 6.64% -8.90% -302.56%
NOPAT Growth		 -5.26% 20.68% -46.30% 28.07% 26.25% 14.99% 52.06% 16.95% 5.03% -10.35% 14.89%
Net Income Growth		 -2.83% 23.10% -49.09% 25.06% 26.54% 13.55% 123.83% 21.69% 3.44% -11.93% -271.90%
EPS Growth		 -1.35% 24.04% -45.54% 27.16% 29.33% 16.46% 122.45% 25.42% 5.66% -7.58% -269.70%
Operating Cash Flow Growth		 57.51% 56.14% 72.76% 26.00% 6.73% 33.14% 78.05% 22.89% -15.80% -35.21% 179.64%
Free Cash Flow Firm Growth		 96.57% 115.19% 173.07% 273.83% 1,768.70% 258.63% -103.25% -118.47% -160.01% -217.80% -5,240.16%
Invested Capital Growth		 -9.34% -15.65% -32.85% -31.61% -33.63% -31.42% -14.21% -4.40% 10.10% 17.70% 21.81%
Revenue Q/Q Growth		 6.80% 5.32% 8.18% 3.98% 4.73% 4.60% 3.52% 3.07% 4.74% 6.77% 6.92%
EBITDA Q/Q Growth		 7.22% -5.01% -97.97% 60.76% 10.58% -24.97% 167.66% -198.84% -10.80% -49.70% 24.98%
EBIT Q/Q Growth		 6.65% -4.42% -81.39% 56.94% 9.46% -20.45% 142.79% -265.90% -9.25% -40.89% 20.68%
NOPAT Q/Q Growth		 6.25% -4.07% -81.89% 59.47% 3.88% -19.96% -2.57% 29.78% -9.90% -39.40% 20.89%
Net Income Q/Q Growth		 7.00% -5.78% -88.10% 59.50% 8.83% -24.48% 151.85% -233.09% -12.41% -44.30% 20.38%
EPS Q/Q Growth		 7.41% -5.33% -86.08% 59.86% 10.17% -24.53% 150.00% -233.33% -13.64% -42.00% 21.13%
Operating Cash Flow Q/Q Growth		 -10.96% 15.45% 67.16% -140.20% -39.87% 39.40% 89.22% -743.86% -110.04% 29.24% 106.35%
Free Cash Flow Firm Q/Q Growth		 88.94% 466.28% 138.74% 79.75% 6.16% -21.28% -102.16% -946.66% -237.13% -54.53% 2.07%
Invested Capital Q/Q Growth		 -2.83% -4.34% -24.39% -2.69% -5.69% -1.16% -5.41% 7.58% 9.46% 5.66% -2.10%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 40.51% 41.01% 43.30% 45.14% 48.29% 49.60% 53.40% 51.35% 52.05% 51.59% 52.76%
EBITDA Margin		 -54.32% -54.16% -99.11% -37.41% -31.94% -38.16% 24.94% -23.92% -25.30% -35.47% -24.89%
Operating Margin		 -65.70% -64.92% -109.16% -42.55% -39.05% -44.79% -31.36% -30.23% -31.73% -41.42% -30.65%
EBIT Margin		 -65.75% -65.19% -109.30% -45.26% -39.13% -45.06% 18.63% -29.98% -31.27% -41.27% -30.61%
Profit (Net Income) Margin		 -60.15% -60.41% -105.04% -40.91% -35.61% -42.38% 21.23% -27.41% -29.42% -39.76% -29.61%
Tax Burden Percent		 100.28% 100.76% 100.22% 99.72% 100.31% 100.45% 99.07% 100.95% 100.84% 100.10% 100.90%
Interest Burden Percent		 91.24% 91.97% 95.89% 90.63% 90.74% 93.64% 115.04% 90.57% 93.29% 96.26% 95.86%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.93% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -41.15% -43.26% -89.84% -38.57% -38.90% -48.47% -60.06% -41.84% -44.72% -59.62% -48.26%
ROIC Less NNEP Spread (ROIC-NNEP)		 -38.45% -39.95% -82.63% -35.50% -36.38% -44.75% -76.95% -39.65% -41.86% -54.83% -44.69%
Return on Net Nonoperating Assets (RNNOA)		 21.57% 21.52% 46.51% 19.85% 20.24% 24.63% 47.20% 23.68% 24.01% 30.43% 26.12%
Return on Equity (ROE)		 -19.57% -21.74% -43.33% -18.73% -18.66% -23.84% -12.86% -18.16% -20.71% -29.19% -22.14%
Cash Return on Invested Capital (CROIC)		 -42.60% -32.67% -26.19% -26.42% -22.48% -25.34% -37.89% -45.57% -58.03% -65.05% -72.54%
Operating Return on Assets (OROA)		 -21.00% -23.24% -44.55% -20.37% -19.26% -24.13% 10.53% -17.97% -19.64% -26.57% -20.09%
Return on Assets (ROA)		 -19.21% -21.54% -42.82% -18.41% -17.53% -22.70% 12.00% -16.43% -18.48% -25.60% -19.43%
Return on Common Equity (ROCE)		 -19.57% -21.74% -43.33% -18.73% -18.66% -23.84% -12.86% -18.16% -20.71% -29.19% -22.14%
Return on Equity Simple (ROE_SIMPLE)		 -34.88% -34.30% -44.86% 0.00% -43.28% -43.43% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -33 -34 -62 -25 -24 -29 -30 -21 -23 -32 -25
NOPAT Margin		 -45.99% -45.45% -76.41% -29.78% -27.34% -31.35% -31.07% -21.16% -22.21% -29.00% -21.45%
Net Nonoperating Expense Percent (NNEP)		 -2.70% -3.31% -7.22% -3.08% -2.52% -3.72% 16.90% -2.19% -2.86% -4.80% -3.58%
Return On Investment Capital (ROIC_SIMPLE)		 -5.57% - - - -5.32% -6.61% -6.24% -4.43% -5.05% -7.05% -5.70%
Cost of Revenue to Revenue		 59.49% 58.99% 56.70% 54.86% 51.71% 50.40% 46.60% 48.65% 47.95% 48.41% 47.24%
SG&A Expenses to Revenue		 73.90% 73.87% 69.72% 62.73% 63.32% 68.62% 65.97% 64.40% 67.25% 68.72% 68.18%
R&D to Revenue		 32.31% 32.07% 27.58% 24.95% 24.02% 25.77% 18.79% 17.18% 16.52% 17.79% 15.23%
Operating Expenses to Revenue		 106.21% 105.93% 152.45% 87.68% 87.34% 94.39% 84.76% 81.58% 83.77% 93.02% 83.41%
Earnings before Interest and Taxes (EBIT)		 -47 -49 -89 -38 -35 -42 18 -30 -32 -46 -36
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -39 -41 -81 -32 -28 -35 24 -24 -26 -39 -29
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.59 3.54 5.84 5.60 6.05 5.32 4.61 3.59 4.25 6.40 14.37
Price to Tangible Book Value (P/TBV)		 4.69 4.70 7.35 7.11 7.75 6.88 5.77 4.50 5.38 8.10 18.26
Price to Revenue (P/Rev)		 8.06 7.15 9.72 8.46 8.35 6.74 6.08 4.51 4.95 7.12 14.84
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 6.47 6.34 12.79 12.08 13.44 11.39 10.97 7.58 8.28 12.42 29.28
Enterprise Value to Revenue (EV/Rev)		 6.88 6.09 8.74 7.57 7.53 6.00 5.24 3.75 4.31 6.53 14.29
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.56 -0.54 -0.56 -0.56 -0.56 -0.55 -0.61 -0.60 -0.57 -0.56 -0.58
Leverage Ratio		 1.23 1.23 1.26 1.27 1.28 1.30 1.32 1.33 1.37 1.42 1.42
Compound Leverage Factor		 1.12 1.13 1.21 1.15 1.16 1.22 1.52 1.20 1.28 1.37 1.37
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 7.51 6.79 9.61 9.23 8.81 6.83 6.31 4.04 4.30 5.76 14.80
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.98 5.51 4.91 4.88 4.96 4.51 3.90 3.64 3.78 2.70 2.67
Quick Ratio		 5.31 4.88 4.36 4.38 4.45 4.10 3.45 3.17 3.08 1.97 1.93
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -4.17 15 36 65 70 55 -1.18 -12 -42 -64 -63
Operating Cash Flow to CapEx		 -1,525.43% -3,221.06% -660.93% -765.23% -944.80% -313.37% -15.28% -95.07% -248.79% -136.25% 11.42%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 2,258.58 2,897.22 382.77 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 -528.28 -892.83 -90.81 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 -597.31 -987.33 -119.79 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.32 0.36 0.41 0.45 0.49 0.54 0.57 0.60 0.63 0.64 0.66
Accounts Receivable Turnover		 6.58 6.59 7.92 7.93 8.84 8.09 8.85 8.19 8.76 7.18 7.52
Inventory Turnover		 4.47 4.87 5.42 6.40 6.73 7.23 6.76 7.08 6.71 7.22 6.79
Fixed Asset Turnover		 1.94 2.07 2.39 2.67 2.91 3.18 3.59 3.68 3.81 3.93 4.17
Accounts Payable Turnover		 11.47 16.35 18.67 22.91 21.83 23.51 19.76 29.17 18.95 17.26 14.29
Days Sales Outstanding (DSO)		 55.50 55.36 46.10 46.05 41.27 45.11 41.23 44.55 41.66 50.85 48.57
Days Inventory Outstanding (DIO)		 81.74 74.93 67.40 57.04 54.24 50.46 54.02 51.52 54.38 50.57 53.76
Days Payable Outstanding (DPO)		 31.81 22.32 19.55 15.93 16.72 15.53 18.47 12.51 19.27 21.15 25.54
Cash Conversion Cycle (CCC)		 105.43 107.97 93.94 87.15 78.80 80.04 76.77 83.56 76.77 80.27 76.79
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 279 267 202 196 185 183 173 186 204 215 211
Invested Capital Turnover		 0.89 0.95 1.18 1.30 1.42 1.55 1.93 1.98 2.01 2.06 2.25
Increase / (Decrease) in Invested Capital		 -29 -49 -99 -91 -94 -84 -29 -8.58 19 32 38
Enterprise Value (EV)		 1,804 1,690 2,580 2,371 2,487 2,085 1,899 1,412 1,687 2,674 6,172
Market Capitalization		 2,116 1,984 2,869 2,647 2,758 2,342 2,204 1,699 1,940 2,914 6,406
Book Value per Share		 $10.26 $9.69 $8.44 $8.07 $7.68 $7.38 $7.98 $7.84 $7.46 $7.42 $7.16
Tangible Book Value per Share		 $7.84 $7.31 $6.71 $6.36 $6.00 $5.71 $6.38 $6.25 $5.90 $5.87 $5.63
Total Capital		 590 560 491 473 456 440 478 473 456 455 446
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -311 -293 -289 -276 -271 -257 -305 -287 -252 -240 -235
Capital Expenditures (CapEx)		 1.51 0.60 0.97 2.00 2.27 4.14 9.17 12 9.97 13 9.76
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 14 11 -1.34 -0.63 4.84 6.32 1.91 9.13 25 32 34
Debt-free Net Working Capital (DFNWC)		 325 304 288 276 276 263 253 242 223 203 201
Net Working Capital (NWC)		 325 304 288 276 276 263 253 242 223 203 201
Net Nonoperating Expense (NNE)		 10 11 23 9.42 7.34 10 -50 6.18 7.48 12 9.66
Net Nonoperating Obligations (NNO)		 -311 -293 -289 -276 -271 -257 -305 -287 -252 -240 -235
Total Depreciation and Amortization (D&A)		 8.17 8.30 8.30 6.66 6.38 6.40 6.07 6.00 6.19 6.41 6.78
Debt-free, Cash-free Net Working Capital to Revenue		 5.28% 3.98% -0.46% -0.20% 1.46% 1.82% 0.53% 2.42% 6.51% 7.76% 7.92%
Debt-free Net Working Capital to Revenue		 123.87% 109.69% 97.58% 88.11% 83.49% 75.78% 69.76% 64.15% 57.06% 49.69% 46.56%
Net Working Capital to Revenue		 123.87% 109.69% 97.58% 88.11% 83.49% 75.78% 69.76% 64.15% 57.06% 49.69% 46.56%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.75) ($0.79) ($1.47) ($0.59) ($0.53) ($0.66) $0.34 ($0.45) ($0.50) ($0.71) ($0.56)
Adjusted Weighted Average Basic Shares Outstanding		 57.50M 57.78M 58.15M 58.02M 59.16M 59.65M 60.00M 59.81M 61.08M 61.70M 62.40M
Adjusted Diluted Earnings per Share		 ($0.75) ($0.79) ($1.47) ($0.59) ($0.53) ($0.66) $0.33 ($0.44) ($0.50) ($0.71) ($0.56)
Adjusted Weighted Average Diluted Shares Outstanding		 57.50M 57.78M 58.15M 58.02M 59.16M 59.65M 61.16M 59.81M 61.08M 61.70M 62.40M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 57.82M 58.23M 58.59M 59.36M 59.65M 59.92M 60.36M 61.15M 61.31M 62.27M 62.71M
Normalized Net Operating Profit after Tax (NOPAT)		 -33 -34 -31 -25 -24 -29 -30 -21 -23 -27 -25
Normalized NOPAT Margin		 -45.99% -45.45% -37.80% -29.78% -27.34% -31.35% -31.07% -21.16% -22.21% -24.44% -21.45%
Pre Tax Income Margin		 -59.98% -59.95% -104.81% -41.02% -35.50% -42.19% 21.43% -27.15% -29.18% -39.72% -29.35%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 -1,322.14 -1,446.38 -292.38 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 -870.00 -1,010.45 -203.44 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 -1,391.17 -1,540.88 -321.36 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 -939.04 -1,104.95 -232.42 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -2.83% -3.18% -2.31% -1.90% -0.79% -0.01% -0.03% -0.02% -0.02% -0.02% -0.01%

Financials Breakdown Chart

Key Financial Trends

Twist Bioscience’s revenue growth remains strong, but the company has not yet achieved sustainable profitability. Revenue increased from $56.1 million in Q3 2022 to $118.4 million in Q3 2026, representing more than a doubling over the period. In fiscal 2026, quarterly revenue also rose from $103.7 million in Q1 to $110.7 million in Q2 and $118.4 million in Q3. This growth is a clear strength for the business.

Gross profit has expanded alongside revenue, reaching $62.5 million in Q3 2026 compared with $21.9 million in Q3 2022. However, gross margin has recently held near 53%, while operating expenses remain significantly higher than gross profit. Selling, general and administrative costs were $80.7 million in Q3 2026, and research and development expense was $18.0 million, resulting in a $36.3 million operating loss.

Net losses have improved from the particularly weak results in 2022 and early 2023, but Twist continues to report losses every quarter in the latest fiscal year. The Q3 2026 net loss of $35.1 million improved from $44.0 million in Q2 and $30.5 million in Q1 on a sequential basis, although it was larger than the $27.1 million loss reported in Q4 2025. The comparison with Q3 2025 is less meaningful because that quarter included $48.0 million of other income and was subsequently restated.

Cash flow trends are showing some improvement. Operating cash flow was positive at $1.1 million in Q3 2026 after outflows of $17.6 million in Q2, $24.8 million in Q1 and $11.8 million in Q4 2025. Still, the company spent $9.8 million on property and equipment during Q3, and total cash and cash equivalents declined to $117.4 million from $148.6 million at the end of Q1.

The balance sheet remains well-capitalized relative to current obligations. Cash, short-term investments and long-term investments totaled approximately $234.9 million at June 30, 2026, compared with total liabilities of $226.7 million. Total current assets of $321.3 million were roughly 2.7 times total current liabilities of $120.3 million. Nevertheless, the company’s liquidity has declined substantially from 2022 and early 2024 levels as operating losses and capital spending continue to consume cash.

  • Strong top-line momentum: Quarterly revenue more than doubled from $56.1 million in Q3 2022 to $118.4 million in Q3 2026, with sequential growth throughout fiscal 2026.
  • Improving gross profit: Gross profit increased to $62.5 million in Q3 2026 from $21.9 million in Q3 2022, while gross margin has generally remained around the low-50% range recently.
  • Operating cash flow improved materially: Twist generated $1.1 million of operating cash flow in Q3 2026, its strongest result among the latest four reported quarters and a significant improvement from the $17.6 million outflow in Q2.
  • Low near-term balance-sheet pressure: Current assets of $321.3 million exceeded current liabilities of $120.3 million by a wide margin, providing financial flexibility while the company works toward profitability.
  • Substantial investment portfolio: Cash and investments totaled approximately $234.9 million at the end of Q3 2026, giving Twist resources to fund research, equipment purchases and ongoing operations.
  • Capital spending remains elevated: Property and equipment purchases ranged from approximately $9.2 million to $12.9 million in the latest fiscal-year quarters, indicating continued investment in capacity but also increasing cash requirements.
  • Investment income is supporting results: Interest and investment income contributed $1.5 million in Q3 2026, although this benefit is dependent on cash balances and market interest rates rather than core operating performance.
  • Persistent operating losses: Twist reported a $36.3 million operating loss in Q3 2026, and operating losses have continued in every quarter shown in the data set.
  • Net losses continue to reduce retained earnings: Retained earnings declined to negative $1.43 billion at June 30, 2026, reflecting the company’s accumulated history of losses.
  • Share dilution is a continuing concern: Weighted-average basic shares increased from 53.9 million in Q4 2022 to 62.4 million in Q3 2026, while the company continues to receive cash from issuing common equity.

For investors, the central question is whether Twist can convert its rapidly growing revenue and improving gross profit into consistent operating cash flow and eventual profitability. The Q3 2026 cash-flow improvement is encouraging, but continued operating losses, capital spending and equity issuance remain important risks.

08/30/26 02:15 PM ETAI Generated. May Contain Errors.

Twist Bioscience Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Twist Bioscience's fiscal year ends in September. Their fiscal year 2025 ended on September 30, 2025.

Twist Bioscience's net income appears to be on an upward trend, with a most recent value of -$77.67 million in 2025, rising from -$59.31 million in 2017. The previous period was -$208.73 million in 2024. See where experts think Twist Bioscience is headed by visiting Twist Bioscience's forecast page.

Twist Bioscience's total operating income in 2025 was -$136.26 million, based on the following breakdown:
  • Total Gross Profit: $191.00 million
  • Total Operating Expenses: $327.26 million

Over the last 8 years, Twist Bioscience's total revenue changed from $10.77 million in 2017 to $376.57 million in 2025, a change of 3,397.5%.

Twist Bioscience's total liabilities were at $168.90 million at the end of 2025, a 19.3% increase from 2024, and a 531.9% increase since 2018.

In the past 7 years, Twist Bioscience's cash and equivalents has ranged from $46.74 million in 2019 to $465.83 million in 2021, and is currently $183.05 million as of their latest financial filing in 2025.

Over the last 8 years, Twist Bioscience's book value per share changed from 0.00 in 2017 to 7.84 in 2025, a change of 783.6%.


Related Companies

Financial statements for NASDAQ:TWST last updated on 8/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...
Awesomely | Sponsoredtc pixel
Do this before December or regret it
Porter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...
Porter & Company | Sponsoredtc pixel
Now that SpaceX is public, buy this ticker (no, not SpaceX or Tesla)
The SpaceX IPO wasn't the big trade - according to Larry Benedict, founder of The Opportunistic Trader, it was...
Brownstone Research | Sponsoredtc pixel
SPDR Gold just lost $14 billion.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...
Behind the Markets | Sponsoredtc pixel
Buy These Stocks Before August 31st
Keith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...
TradeSmith | Sponsoredtc pixel
Why the Treasury still prices gold at 42 dollars an ounce
The U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...
Golden Portfolio | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel